Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ZAP70 | P43403 | 8/20 | 0.73 |
| ▸ | SYK | P43405 | 8/20 | 0.69 |
| ▸ | JAK2 | O60674 | 2/20 | 0.58 |
| ▸ | ABL1 | P00519 | 2/20 | 0.52 |
| ▸ | NTRK1 | P04629 | 2/20 | 0.52 |
| ▸ | YES1 | P07947 | 2/20 | 0.52 |
| ▸ | KDR | P35968 | 2/20 | 0.52 |
| ▸ | BTK | Q06187 | 1/20 | 0.49 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.49 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.49 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.49 |
| ▸ | PIM1 | P11309 | 1/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.48 |
| ▸ | HIPK1 | Q86Z02 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1051560 | 0.95 | SYK (0.75) | ZAP70SYKJAK2BTKPIK3CD | |
| SCHEMBL1059712 | 0.92 | SYK (0.63) | ZAP70SYKJAK2BTKPIK3CD | |
| SCHEMBL1058366 | 0.91 | SYK (0.68) | ZAP70SYKJAK2BTKPIK3CD | |
| SCHEMBL1058105 | 0.91 | SYK (0.70) | ZAP70SYKJAK2BTKPIK3CD | |
| SCHEMBL1058426 | 0.91 | SYK (0.70) | ZAP70SYKJAK2BTKPIK3CD | |
| SCHEMBL1059337 | 0.91 | SYK (0.62) | ZAP70SYKJAK2ABL1NTRK1 | |
| SCHEMBL1059206 | 0.91 | SYK (0.62) | ZAP70SYKJAK2NTRK1BTK | |
| SCHEMBL1058391 | 0.91 | SYK (0.69) | ZAP70SYKJAK2BTKPIK3CD | |
| SCHEMBL1058792 | 0.91 | SYK (0.72) | ZAP70SYKJAK2BTKPIK3CD | |
| SCHEMBL1059093 | 0.90 | SYK (0.65) | ZAP70SYKJAK2BTKPIK3CD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8354526-B2 | Pyrido [4, 3-D] pyrimidinone derivatives as kinase inhibitors | IRM LLC (BM) | 2013-01-15 | — | — | US | claimed |
| US-20110003790-A1 | PYRIDO [4, 3-D] PYRIMIDINONE DERIVATIVES AS KINASE INHIBITORS | IRM LLC (BM) | 2011-01-06 | — | — | US | claimed |
| EP-2250169-A1 | PYRIDO [4, 3-D]PYRIMIDINONE DERIVATIVES AS KINASE INHIBITORS | IRM LLC (BM) | 2010-11-17 | — | — | EP | claimed |
| WO-2009099801-A1 | PYRIDO [4, 3-D] PYRIMIDINONE DERIVATIVES AS KINASE INHIBITORS | IRM LLC (BM) | 2009-08-13 | — | — | WO | claimed |
| US-8354526-B2 | Pyrido [4, 3-D] pyrimidinone derivatives as kinase inhibitors | IRM LLC (BM) | 2013-01-15 | — | — | US | disclosed |
| US-8354526-B2 | Pyrido [4, 3-D] pyrimidinone derivatives as kinase inhibitors | IRM LLC (BM) | 2013-01-15 | — | — | US | disclosed |
| US-8354526-B2 | Pyrido [4, 3-D] pyrimidinone derivatives as kinase inhibitors | IRM LLC (BM) | 2013-01-15 | — | — | US | disclosed |
| US-20110003790-A1 | PYRIDO [4, 3-D] PYRIMIDINONE DERIVATIVES AS KINASE INHIBITORS | IRM LLC (BM) | 2011-01-06 | — | — | US | disclosed |
| US-20110003790-A1 | PYRIDO [4, 3-D] PYRIMIDINONE DERIVATIVES AS KINASE INHIBITORS | IRM LLC (BM) | 2011-01-06 | — | — | US | disclosed |
| US-20110003790-A1 | PYRIDO [4, 3-D] PYRIMIDINONE DERIVATIVES AS KINASE INHIBITORS | IRM LLC (BM) | 2011-01-06 | — | — | US | disclosed |
| EP-2250169-A1 | PYRIDO [4, 3-D]PYRIMIDINONE DERIVATIVES AS KINASE INHIBITORS | IRM LLC (BM) | 2010-11-17 | — | — | EP | disclosed |
| WO-2009099801-A1 | PYRIDO [4, 3-D] PYRIMIDINONE DERIVATIVES AS KINASE INHIBITORS | IRM LLC (BM) | 2009-08-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110003790-A1 | PYRIDO [4, 3-D] PYRIMIDINONE DERIVATIVES AS KINASE INHIBITORS | ZAP70, FLT3, LCK | ZAP70 1/4885SYK 18/4885JAK2 58/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.